Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0.00 | $6.36M | $0.00 |
| Revenue growth | — | — | — | — | — | — | — | — | — | -100.0% |
| Operating income | -$9.84M | -$20.4M | -$47.6M | -$50.6M | -$33.5M | -$66.0M | -$34.4M | -$17.3M | -$2.47M | -$6.44M |
| Operating margin | — | — | — | — | — | — | — | — | -38.8% | — |
| Net income | -$9.85M | -$21.2M | -$47.2M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$17.1M | -$3.14M | -$6.00M |
| Net margin | — | — | — | — | — | — | — | — | -49.4% | — |
| EPS (diluted) | -$2.60 | -$4.75 | -$1.45 | -$1.34 | -$0.86 | -$38.15 | -$16.65 | -$6.63 | -$0.84 | -$0.49 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.84M | -$15.9M | -$31.4M | -$39.4M | -$28.2M | -$35.0M | -$31.8M | -$14.3M | -$4.71M | -$6.33M |
| Capital expenditures | $36.0K | $237K | $235K | $40.0K | — | $89.0K | $66.0K | — | — | — |
| Free cash flow | -$8.88M | -$16.2M | -$31.6M | -$39.4M | — | -$35.1M | -$31.9M | — | — | — |
| Dividends paid | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.21M | $24.0M | $48.6M | $22.5M | $24.7M | $42.3M | $19.2M | $1.13M | $111K | $4.79M |
| Total assets | $3.13M | $24.8M | $50.7M | $58.9M | $26.5M | $45.1M | $21.1M | $1.71M | $2.98M | $5.27M |
| Total liabilities | $4.67M | $4.97M | $7.81M | $22.7M | $16.2M | $22.8M | $31.8M | $24.3M | $27.3M | $17.2M |
| Long-term debt | — | — | — | $10.5M | $6.38M | $12.0M | $8.56M | $1.61M | $0.00 | $0.00 |
| Shareholders' equity | $610K | $21.4M | $42.9M | $36.2M | $10.2M | $22.4M | -$10.7M | -$22.6M | -$24.3M | -$11.9M |
| Retained earnings | -$17.7M | -$39.0M | -$86.1M | -$137M | -$172M | -$238M | -$274M | -$291M | -$295M | -$301M |
| Shares (wtd avg diluted) | 4.21M | 27.5M | 35.9M | 40.0M | 40.2M | 1.75M | 2.17M | 2.57M | 3.76M | 12.3M |
Every figure is extracted from Eloxx Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.